#	Pagina
attuale pagina	/open-h2020/projects/207912/index.html
-1	/open-consip/fornitori/2016/profilo-02106930833/index.html

Opendata, web and dolomites

SpheroPredict

A 3D advanced test for prediction of drug response in secondary liver cancer

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

SpheroPredict project word cloud

Explore the words cloud of the SpheroPredict project. It provides you a very rough idea of what is the project "SpheroPredict" about.

patients locations migrating death personalised inefficient quality dealing drug installing deathliest designed cycle productivity incurred cells secondary diseases therapy primary survival guideline created perspectives biologically spheropredict drugs efficacy economic options century medicine causes risked chemotherapy warrant error regarding urgent era liver feasibility tumour commercial financial alleviate therapies clear treatment de burden risk cancers model efficient metastasizing line spheroid types spherotec entail chemoresistance predict innovative time proven international trial body deaths commercialisation toxicity lack published micro patient first accurate fail cancer metastatic individualised 21st guidelines healthcare life solution heterogeneous 3d worldwide treatments treat platform tumours

Project "SpheroPredict" data sheet

The following table provides information about the project.

Coordinator	SPHEROTEC GMBH Organization address address: AM KLOPFERSPITZ 19 city: MARTINSRIED postcode: 82152 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Germany [DE]
Project website	http://www.spherotec.com/ - www.spheromed.com - www.spheroselect.com
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2016-2017
Funding Scheme	SME-1
Starting year	2017
Duration (year-month-day)	from 2017-01-01 to 2017-04-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	SPHEROTEC GMBH SPHEROTEC GMBH Organization address address: AM KLOPFERSPITZ 19 city: MARTINSRIED postcode: 82152 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MARTINSRIED)	coordinator	50˙000.00

Map

Project objective

Cancer remains one of the deathliest diseases of the 21st century, with more than 1.9 M deaths per year in Europe. Some tumours entail a high risk of metastasizing, meaning that they are able to reach other locations in the body. Migrating cells from a primary tumour often cause secondary cancer in the liver, which is one of the leading causes of death worldwide.Regarding treatment options, international institutions have published clear guidelines about first line treatments to treat particular types of primary cancers. However, when dealing with secondary cancers (like metastatic liver cancer) there is a heterogeneous and very wide range of treatment options and no clear guidelines. The choice of treatment in secondary cancer is based in “trial and error”. This “trial and error” approach causes many patients fail to respond to therapy due to chemoresistance (lack of response to chemotherapy). In response, we at SpheroTec have created SpheroPredict, an individualised drug testing platform designed to predict the patient’s response to guideline therapies before installing the treatment cycle. Using cancer cells from the patient’s tumour, we build an accurate and biologically relevant 3D micro-tumour (spheroid) model to test the drugs and analyse the response in advance. In the end, only drugs with proven efficacy and low toxicity will be applied in the patient’s therapy cycle. In the era of personalised medicine and with the urgent need for de-risked and efficient drug treatments, we have developed an innovative solution that will greatly improve the patient’s survival time, quality of life and will help to alleviate the economic burden on the EU healthcare system incurred by inefficient therapies and productivity loss. Thus, in Phase 1, we aim to warrant the feasibility of the SpheroPredict project from the technical, commercial and financial perspectives, in order to ensure its success upon commercialisation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SPHEROPREDICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SPHEROPREDICT" are provided by the European Opendata Portal: CORDIS opendata.